SPRC - Psyched: Psilocybin Therapy For Depression UK Rescheduling US Policy Reform And More | Benzinga
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Nonprofit medical research organization the Usona Institute shared the results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for 104 adults with Major Depressive Disorder (MDD,) providing further evidence of the psychedelic’s antidepressant capabilities.
COMPASS Pathways (NASDAQ: CMPS), one of the biggest players in the psychedelics biotech space today, shared the results from research on the potential of its novel AI technologies to support proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression (TRD.)
Meanwhile, U.K. drug policy and reform is underway through several paths. On August 30, Parliament’s Home Affairs committee presented a report urging the reclassification of psilocybin mushrooms and other psychedelics to Schedule 2 to support the "growing body of evidence” with further clinical research on the substances’ potential medical and therapeutic benefits.
Psychedelics Reform Update: CA Bill's Final Vote, MA 2024 Legalization Ballot, HI Task Force, OR Funding And More
A number of states are moving reform bills concerning the study or straight out legalizing the use of psychedelic substances for therapeutic purposes. Others have already passed legislation and its implementation is underway. Here’s a short recap of the latest moves as of Sept. 7.
The Milestone Round
-
Cybin's (NYSE: CYBN) intellectual powerhouse grows with a new US patent covering deuterated 5-MeO-DMT.
-
Optimi Health (OTCMKTS: OPTHF) will supply psychedelics to Canada's SAP, while simultaneously securing a CA$1M private financing.
-
Johns Hopkins University will work with Clearmind Medicine (NASDAQ: CMND) on the latter’s alcohol ...